Kynexis
An Rykx has extensive experience in clinical development, holding various leadership roles such as Clinical Trial Manager at Kynexis and Senior R&D Leader in Clinical Development at 2 Bridge. Previous positions include Clinical Project Leader at Novalon and Sr. Clinical Scientist at Shire Pharmaceuticals, where Rykx also served as Clinical Scientist. Additionally, Rykx worked as Late Development Project Manager at Movetis NV. An Rykx earned a PhD in Medical Sciences and a Master's degree in Biochemistry from KU Leuven, graduating in 2006 and 2000, respectively.
This person is not in any offices
Kynexis
Kynexis is advancing precision therapeutics for brain diseases by taking a biomarker-based approach to advance a potential first-in-class treatment for cognitive impairment associated with schizophrenia (CIAS). By harnessing large data to identify and stratify patients based on the underlying causal human. biology of the disease, Kynexis is targeting KAT-II, a key enzyme in the kynurenine pathway. The company’s lead candidate, KYN-5356, is a first-in-class small molecule that is potent and highly selective for KAT-II.